Statements (218)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:disease
gptkb:psychotherapy gptkb:neurodegenerative_diseases |
| gptkbp:affects |
gptkb:Heart
gptkb:movement gptkb:computer gptkb:memory behavior motor neurons cognitive function kidneys cognition social interactions language skills financial decision-making decision-making abilities behavior and emotions |
| gptkbp:associated_with |
environmental factors
age genetic factors transthyretin protein gender (more common in men) |
| gptkbp:can_be_reversible_in |
some cases
|
| gptkbp:can_lead_to |
social isolation
confusion loss of independence changes in personality increased dependency difficulty in daily activities |
| gptkbp:cause |
memory loss
death of motor neurons loss of dopamine-producing neurons death in older adults disability in older adults progressive paralysis |
| gptkbp:caused_by |
gptkb:neurodegenerative_diseases
Huntington's disease genetic mutations neurofibrillary tangles accumulation of amyloid plaques vascular issues |
| gptkbp:challenges |
healthcare systems
|
| gptkbp:clinical_trial |
drug development
ongoing research biomarker studies symptom management studies |
| gptkbp:condition |
gptkb:frontotemporal_dementia
gptkb:AL_amyloidosis pain spasticity wild-type amyloidosis |
| gptkbp:diagnosis |
genetic testing
brain imaging cognitive tests clinical evaluation biopsy clinical examination cognitive assessments medical history electromyography neurological exams |
| gptkbp:evaluates |
brain imaging techniques
|
| gptkbp:famous_event |
gptkb:Ice_Bucket_Challenge
|
| gptkbp:first_described_by |
gptkb:1952
gptkb:Jean-Martin_Charcot |
| gptkbp:funding |
gptkb:Department_of_Defense
gptkb:National_Institutes_of_Health |
| gptkbp:genetic_studies |
gptkb:FUS_mutations
C9orf72 mutations SOD1 mutations TARDBP mutations |
| gptkbp:has_a_focus_on |
gptkb:medical_research
public awareness campaigns |
| https://www.w3.org/2000/01/rdf-schema#label |
neurodegenerative diseases
|
| gptkbp:impact |
family dynamics
|
| gptkbp:inherits_from |
autosomal dominant
|
| gptkbp:is_a_complex_condition |
gptkb:true
|
| gptkbp:is_a_global_health_issue |
gptkb:true
|
| gptkbp:is_a_growing_concern_in |
aging populations
|
| gptkbp:is_a_public_health_priority |
gptkb:true
|
| gptkbp:is_a_subject_of |
clinical trials
public health campaigns ongoing research ethical discussions |
| gptkbp:is_affected_by |
stress
|
| gptkbp:is_associated_with |
gptkb:depression
anxiety sleep disturbances aging poor nutrition increased caregiver burden |
| gptkbp:is_characterized_by |
amyloid plaques
changes in mood difficulty in communication disorientation neurofibrillary tangles progressive memory loss decline in memory |
| gptkbp:is_common_in |
gptkb:women
|
| gptkbp:is_described_as |
various cognitive impairments
|
| gptkbp:is_documented_in |
gptkb:literature
gptkb:guidelines research studies |
| gptkbp:is_influenced_by |
environmental factors
lifestyle factors genetic factors lifestyle choices social factors |
| gptkbp:is_managed_by |
caregiver education
supportive care lifestyle changes social engagement cognitive training |
| gptkbp:is_often_accompanied_by |
gptkb:depression
anxiety physical health issues sleep disturbances |
| gptkbp:is_often_described_as |
disorientation
|
| gptkbp:is_often_diagnosed_in |
late stages
|
| gptkbp:is_often_discussed_in |
policy discussions.
|
| gptkbp:is_often_seen_in |
elderly population
delirium normal aging |
| gptkbp:is_part_of |
gptkb:neurodegenerative_diseases
dementia spectrum |
| gptkbp:is_recognized_by |
gptkb:Alzheimer's_Association
gptkb:the_World_Health_Organization gptkb:World_Health_Organization |
| gptkbp:is_related_to |
gptkb:Genetics
age family history |
| gptkbp:is_studied_in |
gptkb:psychology
neurology neuropsychology geriatrics |
| gptkbp:is_supported_by |
community resources
|
| gptkbp:known_as |
gptkb:Lou_Gehrig's_disease
gptkb:ALS |
| gptkbp:lifespan |
3 to 5 years after diagnosis
|
| gptkbp:named_after |
gptkb:James_Parkinson
|
| gptkbp:notable_person |
gptkb:Terry_Fox
gptkb:Jason_Becker gptkb:A._J._Styles gptkb:Henry_Fonda gptkb:Pat_Quinn gptkb:Steve_Gleason gptkb:Stephen_Hawking gptkb:Morrissey gptkb:Lou_Gehrig gptkb:David_Niven Glen Mc Mahon |
| gptkbp:premiered_on |
typically between ages 40 and 70
|
| gptkbp:prevalence |
2 per 100,000 people
rare disease 1% of the population over 60 |
| gptkbp:prevention |
healthy lifestyle choices
|
| gptkbp:public_awareness |
gptkb:ALS_Awareness_Month
|
| gptkbp:public_figure_advocacy |
athletes promoting awareness
celebrities raising awareness politicians supporting research funding |
| gptkbp:replaced_by |
gptkb:true
|
| gptkbp:research |
gptkb:gene_therapy
neuroprotective agents stem cell therapy ongoing studies |
| gptkbp:research_focus |
gptkb:gene_therapy
protein misfolding |
| gptkbp:risk_factor |
gptkb:diabetes
gptkb:military age obesity family history smoking gender high blood pressure exposure to toxins lack of physical activity |
| gptkbp:scientific_classification |
different types
|
| gptkbp:support |
gptkb:ALS_Association
gptkb:MDA_(Muscular_Dystrophy_Association) local support groups |
| gptkbp:symptoms |
gptkb:Cardiology
stiffness confusion respiratory failure difficulty speaking muscle weakness difficulty swallowing muscle atrophy peripheral neuropathy tremors renal failure changes in personality balance problems difficulty in planning misplacing items withdrawal from social activities slowness of movement |
| gptkbp:treatment |
gptkb:pharmaceuticals
gptkb:psychotherapy gptkb:riluzole gptkb:edaravone gptkb:surgery liver transplant medications physical therapy cholinesterase inhibitors supportive care chemotherapy specialized facilities |
| gptkbp:type_of |
progressive neurodegenerative disease
|
| gptkbp:bfsParent |
gptkb:Sir_Ronald_Reagan
gptkb:Muhammad_Ali gptkb:National_Institutes_of_Health gptkb:Tony_Bennett gptkb:Nancy_Reagan gptkb:Shinya_Yamanaka |
| gptkbp:bfsLayer |
3
|